ALArnstein Lindaas

Arnstein Lindaas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arnstein Lindaas has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older

    by Rowan McEvoy, Jessica Rose Hervol, Yike Zhang, Emma M. Wagner, Arnstein Lindaas, Yixin Jiao, Stanley Xu, Eric S. Weintraub, Lei Qian, Vennis Hong, et al.

  • Letter to the Editor in Response to Zhao et al

    by Lindsay Zielinski, Kristin Andrejko, Nong Shang, Soyoun Park, Gordana Derado, Arnstein Lindaas, Yuanxin Zhang, Bradley Lufkin, Yoganand Chillarige, Miwako Kobayashi

  • Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care

    by Lindsay Zielinski, Kristin Andrejko, Nong Shang, Soyoun Park, Gordana Derado, Arnstein Lindaas, Yuanxin Zhang, Bradley Lufkin, Yoganand Chillarige, Miwako Kobayashi

    Background: Pneumonia causes high rates of hospitalization among adults living in long-term care (LTC) facilities and is a major cause of mortality in this population. Since 2014, pneumococcal conjugate vaccines (PCVs) have been recommended for US adults aged ≥65 years; however, effectiveness of PCVs against all-cause pneumonia hospitalization among adults living in LTC remains unclear. Methods: We used Medicare Fee-for-Service claims data to construct an open cohort of beneficiaries aged ≥65 years between September 2014 and December 2019. We estimated 13-valent PCV (PCV13) vaccine effectiveness (VE) by comparing rates of pneumonia hospitalization among PCV13-exposed and PCV13-unexposed time during LTC stays. Discrete-time logistic regression models with generalized estimating equations were used to estimate VE, incorporating time-varying exposures and covariates. Results: Among 3 485 071 beneficiaries meeting the eligibility criteria, the proportion vaccinated with PCV13 increased from 1.1% to 52.7% during the study period. The characteristics of beneficiaries with shorter LTC stays differed from those with longer LTC stays: a lower proportion of beneficiaries aged ≥85 years (LTC stay ≤100 vs >100 days: 38.5% vs 48.2%), but a higher proportion with chronic medical conditions (71.4% vs 66.4%), immunocompromising conditions (36.6% vs 25.2%), and recent hospitalizations (84.1% vs 74.7%). Vaccine effectiveness of PCV13 only against all-cause pneumonia hospitalization was 3.8% (95% CI 2.4%–5.2%) overall: 5.6% (3.9%–7.2%) for LTC stays ≤100 days and 0.3% (−2.1%–2.77%) for LTC stays >100 days. Conclusions: 13-Valent PCV reduced the risk of pneumonia hospitalization among this population. Differences in beneficiary characteristics could explain differences in VE by length of LTC stay.


  • Open Access

    Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries

    by Yun Lu, Arnstein Lindaas, Hector S. Izurieta, Myrna Cozen, Mikhail Menis, Xiangyu Shi, Whitney R. Steele, Michael Wernecke, Yoganand Chillarige, Jeffrey A. Kelman, et al.

    Purpose: To characterize long‐term effects of COVID‐19 among older adults (aged ≥ 65 years).Methods: This retrospective descriptive study utilized Medicare Fee‐for‐Service beneficiaries' claims to characterize post‐COVID condition diagnosis code usage, long COVID (defined as post‐COVID condition diagnoses made ≥ 28 days after an initial COVID‐19 diagnosis) incidence, patient demographics, and concurrent diagnoses.Results: During April 1, 2020 to May 21, 2022, 193 691 (0.6%) of 31 847 927 Medicare beneficiaries were diagnosed with post‐COVID conditions using ICD‐10‐CM diagnosis codes U09.9 and B94.8, regardless of prior COVID‐19 diagnosis. Post‐COVID condition diagnosis rate was higher among nursing home residents (18.7 per 1000 person‐years) than community‐dwelling beneficiaries (2.8). Among community‐dwelling beneficiaries with a post‐COVID condition diagnosis, 17.5% did not have any prior COVID‐19 diagnosis code U07.1 recorded. Among beneficiaries with COVID‐19 diagnosis, there were no significant sex, age, or race/ethnicity differences between those with post‐COVID conditions ≥ 28 days after COVID‐19 (i.e., long COVID) and those without post‐COVID conditions. Certain myopathies and interstitial pulmonary disease codes were disproportionately present concurrently with long COVID compared to COVID‐19.Conclusions: In this large study of 32 million Medicare beneficiaries, we found approximately 194 000 post‐COVID condition diagnoses. Post‐COVID condition diagnosis rate was higher among nursing home residents, highlighting the substantial burden of COVID‐19 in this vulnerable population. Community‐dwelling beneficiaries were less likely to seek medical care for COVID‐19 events than nursing home residents, which may suggest differences in COVID‐19 severity and respiratory disease detection between these populations. Long COVID risk after COVID‐19 infection may be similar across demographic groups.


  • Open Access

    Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron Period

    by Yun Lu, Kathryn Matuska, Rowan McEvoy, Hector S Izurieta, Jessica Rose Hervol, Mikhail Menis, Arnstein Lindaas, Whitney R Steele, Yoganand Chillarige, Michael Wernecke, et al.

    Background: We assessed the added benefit and waning effectiveness of a third COVID-19 vaccine dose (original formula) for preventing COVID-19–related outcomes. Methods: We used Medicare claims data to conduct a retrospective cohort study in US community-dwelling Medicare Fee-for-Service beneficiaries aged ≥65 years during the BA.1/BA.2 Omicron period (19 December 2021–26 March 2022). We estimated relative vaccine effectiveness (RVE) of 3 vs 2 doses of mRNA COVID-19 vaccines using marginal structural Cox regression models. Results: Among 8 129 355 eligible beneficiaries, 73.4% were 3 dose vaccinated by 26 March 2022. At 14 to 60 days since vaccination, a third dose provided significant added benefit against COVID-19–related hospitalization for Moderna (RVE, 77.0%; 95% CI, 75.7%–78.2%) and Pfizer-BioNTech (RVE, 72.3%; 95% CI, 70.6%–73.8%). Added benefit was lower at >120 days. For those with prior medically attended COVID-19 diagnoses, Pfizer-BioNTech provided an added benefit for 120 days, while Moderna provided some added benefit at >120 days. Added benefit for either vaccine was higher against death as compared with less severe outcomes, which still decreased at >120 days. Conclusions: A third-dose COVID-19 vaccine provided significant added benefit against COVID-19–related hospitalization and death, even for beneficiaries with prior medically attended COVID-19 diagnoses. This added benefit decreased after 4 months.


  • Open Access

    Evaluating the Risk of Cardiovascular Adverse Events and Appendicitis After COVID-19 Diagnosis in Adults in the United States: Implications of the Start of Follow-Up

    by J. Bradley Layton, Arnstein Lindaas, Stella G. Muthuri, Patricia C. Lloyd, Morgan M. Richey, Joann F. Gruber, Hai Lyu, Mollie M. McKillop, Lisa S. Kowarski, Christine Bui, et al.

    Purpose: This study evaluated the association between coronavirus disease 2019 (COVID-19) diagnosis and adverse events (AEs), including cardiovascular AEs and appendicitis, in US adults before the introduction of COVID-19 vaccines. Real-world studies of AEs after COVID-19 suggest that diagnoses of AEs and COVID-19 frequently occur on the same day and may be a source of bias. Methods: Cohort and self-controlled risk interval (SCRI) designs were used in 2 US administrative claims data sources—Merative™ MarketScan® (ages 18-64 years) and Medicare (ages ≥ 65 years). AEs included stroke (nonhemorrhagic and hemorrhagic), acute myocardial infarction, myocarditis/pericarditis, deep vein thrombosis, pulmonary embolism (PE), disseminated intravascular coagulation (DIC), unusual-site and common-site thrombosis with thrombocytopenia syndrome, and appendicitis. In cohort analyses, weighted hazard ratios (HRs) and 95% confidence intervals (CIs) compared adults with a COVID-19 diagnosis and matched comparators. In SCRI analysis, relative incidences (RIs) and 95% CIs compared risk and reference windows within individuals. Analyses were performed starting follow-up on Time 0 and Day 1. Results: For cardiovascular AEs, all estimates starting follow-up on Day 1 were above 1.0 in both data sources. For cohort analyses, the strongest associations were for inpatient PE in both databases: MarketScan, HR=8.65 (95% CI, 6.06-12.35), Medicare HR=3.06 (95% CI, 2.88-3.26). For SCRI analyses, the strongest association in MarketScan was for DIC: RI=32.28 (95% CI, 17.06-61.09) and in Medicare was for myocarditis/pericarditis: RI=4.53 (95% CI, 3.89-5.27). AEs diagnosed concurrently with COVID-19 (ie, on Time 0) were common; including Time 0 in follow-up/risk windows resulted in higher RIs, as well as higher HRs for some AEs. However, some AEs (eg, stroke) were more common on Time 0 in the comparator group resulting in lower HRs. Conclusion: COVID-19 diagnoses had moderate to strong associations with cardiovascular AEs and weak or inconsistent associations with appendicitis, although estimates varied by design and methodology.

  • Open Access

    Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta Periods

    by Yun Lu, Arnstein Lindaas, Kathryn Matuska, Hector S Izurieta, Rowan McEvoy, Mikhail Menis, Xiangyu Shi, Whitney R Steele, Michael Wernecke, Yoganand Chillarige, et al.

    Background: Long-term care residents were among the most vulnerable during the COVID-19 pandemic. We estimated vaccine effectiveness of mRNA COVID-19 vaccines in Medicare nursing home residents aged ≥65 years during pre-Delta and high Delta periods. Methods: We conducted a retrospective cohort study from 13 December 2020 to 20 November 2021 using Medicare claims data. Exposures included 2 and 3 doses of Pfizer-BioNTech and Moderna COVID-19 vaccines. We used inverse probability weighting and Cox proportional hazards models to estimate absolute and relative vaccine effectiveness. Results: Two-dose vaccine effectiveness against COVID-19–related death was 69.8% (95% CI, 65.9%‒73.3%) during the pre-Delta period and 55.7% (49.5%‒61.1%) during the high Delta period, without adjusting for time since vaccination. We observed substantial waning of effectiveness from 65.1% (54.2%‒73.5%) within 6 months from second-dose vaccination to 45.2% (30.6%‒56.7%) ≥6 months after second-dose vaccination in the high Delta period. Three doses provided 88.7% (73.5%‒95.2%) vaccine effectiveness against death, and the incremental benefit of 3 vs 2 doses was 74.6% (40.4%‒89.2%) during high Delta. Among beneficiaries with a prior COVID-19 infection, 3-dose vaccine effectiveness for preventing death was 78.6% (50.0%‒90.8%), and the additional protection of 3 vs 2 doses was 70.0% (30.1%‒87.1%) during high Delta. Vaccine effectiveness estimates against less severe outcomes (eg, infection) were lower. Conclusions: This nationwide real-world study demonstrated that mRNA COVID-19 vaccines provided substantial protection against COVID-19–related death. Two-dose protection waned after 6 months. Third doses during the high Delta period provided significant additional protection for individuals with or without a prior COVID-19 infection.


  • Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.

    by Azadeh Shoaibi, Patricia C. Lloyd, Hui-Lee Wong, Tainya C. Clarke, Yoganand Chillarige, Rose Do, Mao Hu, Yixin Jiao, Andrew Kwist, Arnstein Lindaas, et al.


  • Open Access

    Characterization of Long COVID among U.S. Medicare Beneficiaries using Claims Data

    by Yun Lu, Arnstein Lindaas, Hector S Izurieta, Myrna Cozen, Mikhail Menis, Xiangyu Shi, Whitney Steele, Michael Wernecke, Yoganand Chillarige, Jeffrey A Kelman, et al.

    This retrospective study utilized healthcare claims data to investigate the incidence, patient demographics, and concurrent diagnoses associated with long COVID in the U.S. Medicare population. Nearly 194,000 (0.6%) beneficiaries had post-COVID condition diagnoses, with higher rates among nursing home residents. Of those medically attended for COVID-19, 3-5% were diagnosed with post-COVID conditions. We observed minimal demographic differences between those with and without long COVID. When comparing diagnoses concurrent with long COVID and COVID-19, certain codes (G72 and J84) for myopathies and interstitial pulmonary diseases were disproportionately present with long COVID.

  • Open Access

    Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S

    by Azadeh Shoaibi, Patricia C. Lloyd, Hui-Lee Wong, Tainya C. Clarke, Yoganand Chillarige, Rose Do, Mao Hu, Yixin Jiao, Andrew Kwist, Arnstein Lindaas, et al.

    Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations. Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively. Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly. HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.